The company said the agreement with the United Nations-backed public health organization Medicines Patent Pool will allow generic manufacturers to make the pills widely available in 95 low- and middle-income countries, which cover 53% of the world’s population.
The pill, known as PF-07321332 or paxlovid, is given in combination with an older antiviral medicine called ritonavir.
Earlier this month, Pfizer released top-line results for the study, and an interim analysis conducted before the end of the study showed an 89% reduced risk of hospitalization or death from COVID-19 Was. The first 3 days after the onset of symptoms.
RELATED: Pfizer’s COVID-19 pills reduce risk of hospitalization or death by 89%, company says.
“Pfizer does not receive royalties for sales in low-income countries and is subject to all agreements, while COVID-19 is classified by the World Health Organization as a Public Health Emergency of International Concern. We will further relinquish our loyalty to sales in the country,” Pfizer said. in the statement.
Founded 10 years ago by UnitAid, the Drug Patent Pool gives people in low- and middle-income countries quick access to drugs.
Pfizer has yet to submit the pill for approval by the US Food and Drug Administration, but has said it will do so by the end of the month.
Late last month, Merck’s Ridgeback Biotherapeutics and Medicines patent pool announced a voluntary licensing agreement to expand access to the antiviral drug mollupiravir in 105 low- and middle-income countries.
Molnupiravir is an oral COVID-19 antiviral drug for the treatment of severe COVID-19 and mild to moderate COVID-19 by adults at risk of hospitalization. It was approved by the UK Medicines and Healthcare products Regulatory Authority earlier this month, and both companies have requested approval from the US FDA.
Merck, Ridgeback Therapeutics and Emory University (antiviral drug creators and licensees) are public health emergencies in which COVID-19 is an international concern under the World Health Organization classification. Unless you get royalties for these sales. said.
Pfizer signs a license agreement to provide broader global access to experimental COVID-19 antivirals
SourceLink Pfizer signs a license agreement to provide broader global access to experimental COVID-19 antivirals